Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Pancreatic Neuroendocrine Tumors

Johannes Czernin – Pancreatic Neuroendocrine Tumors Andrei Iagaru – Pancreatic Neuroendocrine Tumors

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver Neoadjuvant PRRT With Y-90-DOTATOC in pNET EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors Study of RYZ101 Compared With SOC in Pts With Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors Lutathera in People With Pancreatic Neuroendocrine Tumors That Have Spread to the Liver Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging – A Report of Accuracy Community-based Neuroendocrine Tumor (NET) Research Study A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms Trial Assessing Roux-en-Y Anastomosis of the Pancreatic Stump to Prevent Pancreatic Fistula Following Distal Pancreatectomy Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Safety and Efficacy of an Ablation Catheter for the Treatment of Pancreatic Premalignant Cyctic Lesions. Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies – Component 1 Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors 68Ga-OPS202 Study for Diagnostic Imaging of GEP NET Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors Pasireotide Treatment for Neuroendocrine Tumor Database ITANET – ENETS Registry Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms Biomarker Study of Pancreatic Neuroendocrine Tumours RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET) Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment 177Lutethium – Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.